Activity Summary:

Patients with interferon gamma (IFN–γ) driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Activity Summary:

Patients with interferon gamma (IFN–γ) driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Activity Summary:
There has been unprecedented research progress in the treatment of hemophilia heralded by the development of non-replacement therapies, emerging factor mimetics, and novel gene therapy agents. In this live, interactive webcast, Dr. Jonathan C. Roberts and Dr. Mindy Simpson will inform and guide on safely integrating recently approved agents into the treatment continuum while ensuring alignment with critical new breakthroughs and enabling patient-focused care pathways.

Activity Summary:
What’s New Doc?: CAR T-cells in Multiple Myeloma, highlights key studies and publications from 2024 on the use of these agents in earlier lines of treatment. Dr. Mikhael details how approved and emerging CAR T cell agents in multiple myeloma will impact the treatment landscape and how to better integrate these agents to enable improved outcomes among patients.

Activity Summary:
There have been multiple key advances in the treatment landscape of chronic lymphocytic leukemia (CLL) in 2024. To that end, a number of double and triple combination studies have been completed or are currently underway and, innovative therapies such as bispecific antibodies and chimeric antigen receptor (CAR) T cells are being developed for CLL. In Highlights and Hindsight in CLL, Dr. Matthew Davids describes the most significant ongoing studies and publications in CLL from 2024 and details their impact on the treatment continuum. This activity enables participants to stay updated on the most relevant breakthroughs to improve outcomes among patients.

Activity Summary:
What’s New Doc?: CAR T-cells in Multiple Myeloma, highlights key studies and publications from 2024 on the use of these agents in earlier lines of treatment. Dr. Mikhael details how approved and emerging CAR T cell agents in multiple myeloma will impact the treatment landscape and how to better integrate these agents to enable improved outcomes among patients.

Activity Summary:
This podcast Clinical Clip features a leading expert highlighting the latest advances in Acute Myeloid Leukemia(AML) treatments presented at the 66th ASH Annual Meeting and Exposition from December 7-10, 2024, in San Diego, CA.

Activity Summary:
There have been multiple key advances in the treatment landscape of chronic lymphocytic leukemia (CLL) in 2024. To that end, a number of double and triple combination studies have been completed or are currently underway and, innovative therapies such as bispecific antibodies and chimeric antigen receptor (CAR) T cells are being developed for CLL. In Highlights and Hindsight in CLL, Dr. Matthew Davids describes the most significant ongoing studies and publications in CLL from 2024 and details their impact on the treatment continuum. This activity enables participants to stay updated on the most relevant breakthroughs and improve outcomes among patients.

Activity Summary:
Clinical Clips in Hemophilia: Cutting-Edge Advances Presented at ASH 2024, will focus on the most exciting abstracts in hemophilia A and B that would be impactful for improved patient care. Dr. Guy Young will discuss the utility of key new evidence on replacement and non-replacement therapy to overcome current limitations and enable improved outcomes among patients.

Activity Summary:
This video Clinical Clip features a leading expert highlighting the latest advances in Acute Myeloid Leukemia(AML) treatments presented at the 66th ASH Annual Meeting and Exposition from December 7-10, 2024, in San Diego, CA.

Activity Summary:
Methamphetamine-associated pulmonary arterial hypertension (MA-PAH) is a serious and increasingly recognized subtype of pulmonary arterial hypertension linked to methamphetamine use. In this on-demand clinical snippet, Dr. Vijay Balasubramanian delves into the epidemiology, clinical characteristics, and hemodynamic challenges of MA-PAH. Participants will gain insights into the global and U.S. trends of methamphetamine use, its associated cardiopulmonary risks, and the mechanisms contributing to vascular toxicity. In addition, this activity addresses current gaps in treatment strategies, challenges in patient adherence, and the need for more comprehensive management approaches, equipping healthcare providers with knowledge to better diagnose and manage this complex condition.

Activity Summary:
Clinical Clips in Hemophilia: Cutting-Edge Advances Presented at ASH 2024, will focus on the most exciting abstracts in hemophilia A and B that would be impactful for improved patient care. Dr. Guy Young will discuss the utility of key new evidence on replacement and non-replacement therapy to overcome current limitations and enable improved outcomes among patients.

Activity Summary:
Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.

Activity Summary:
Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These mini modules address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.

Activity Summary:
Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies were presented at AASLD 2024. In these podcasts, Dr. Ashwani K. Singal will discuss the most important breakthroughs in the understanding and treatment of PBC and will provide guidance on their impact.

Activity Summary:
Vitiligo is a relatively common acquired pigmentation disorder. The therapeutic effect of all the treatment modalities varies considerably from individual to individual. As such, treatment must be individualized. Moreover, vitiligo can carry significant psychosocial impact. Healthcare providers play a crucial role in shaping patients' understanding of their condition, approach to treatment, and coping mechanisms. In this podcast series, Dr. Raj Chovatiya, along with his patient, will discuss ways to individualized treatment strategies and improve holistic care of patients with vitiligo.

Activity Summary:
This podcast series features engaging discussions between leading experts and their patients with primary biliary cholangitis (PBC). The patients share their insights and experiences with PBC, its treatment, and key learning experiences in their journeys with PBC. The activity will enable participants to understand the importance of listening to patient perspectives when designing individualized care pathways to alleviate symptoms and improve quality of life.

Activity Summary:
Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies will be presented at AASLD 2024. In these video Clips, Dr. Ashwani K. Singal will discuss the most important breakthroughs in the understanding and treatment of PBC and will provide guidance on their impact.

Activity Summary:
Despite significant advancements in the management of pulmonary hypertension (PH), several unmet needs remain. Patients continue to face challenges related to symptom control, mental health, and the long-term impacts of both the disease and its treatments. Additionally, there is a critical need for improved global access to care, multidimensional support, and advocacy. In this podcast episode, Dr. Jean Elwing and Dr. Oksana Shlobin discuss these gaps by focusing on the latest updates from the 7th World Symposium on Pulmonary Hypertension (WSPH), offering insights into the latest clinical classifications, risk stratifications, and treatment strategies.

This podcast aims to enhance clinical practice by presenting key research findings, new treatment algorithms, and the implications of emerging therapies. The discussion will include advances in multimodality imaging, genetics, and right ventricular function, highlighting how these innovations improve PH diagnosis and patient management. Through an expert-led presentation and interactive Q&A session, participants will gain a comprehensive understanding of how these developments will shape future research and personalized care for PH patients.

Activity Summary:
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of ‘what you need to know’ podcast episodes from data presented during HIV Drug Therapy, Glasgow 2024.

Activity Summary:
Despite significant advancements in the management of pulmonary hypertension (PH), several unmet needs remain. Patients continue to face challenges related to symptom control, mental health, and the long-term impacts of both the disease and its treatments. Additionally, there is a critical need for improved global access to care, multidimensional support, and advocacy. In this on-demand video, Dr. Jean Elwing and Dr. Oksana Shlobin discuss these gaps by focusing on the latest updates from the 7th World Symposium on Pulmonary Hypertension (WSPH), offering insights into the latest clinical classifications, risk stratifications, and treatment strategies.

This activity aims to enhance clinical practice by presenting key research findings, new treatment algorithms, and the implications of emerging therapies. The discussion will include advances in multimodality imaging, genetics, and right ventricular function, highlighting how these innovations improve PH diagnosis and patient management. Through an expert-led presentation and interactive Q&A session, participants will gain a comprehensive understanding of how these developments will shape future research and personalized care for PH patients.

Activity Summary:
Advances in HIV research often unfold rapidly. To deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational Clinical Clips will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of ‘what you need to know’ videos from data presented during HIV Drug Therapy, Glasgow 2024.

Activity Summary:
Patients with plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1) experience considerable morbidity, a poor quality of life, and increased mortality. Research efforts have led to earlier diagnosis, new monitoring approaches, emerging treatment options, and considerations for surgical intervention. To this end, it is critical that pediatric oncologists as well as other members of the multidisciplinary team neurologists caring for patients with NF1-PN are up to date on recent advances. In this podcast lecture library, Dr. Armstrong uses a case-based discussion to address the heterogeneity and complexity of this condition as well as considerations for the use of emerging therapies when making individualized management decisions among diverse patients.

Activity Summary:
Pulmonary Arterial Hypertension (PAH) remains a significant clinical challenge, particularly in complex cases like PAH-related right heart failure (RHF) and PAH in pregnancy, both of which are associated with high morbidity and mortality. This educational slide kit is designed to address these unmet needs by exploring two complex case studies: a PAH patient with RHF necessitating hospitalization, and a pregnant patient with PAH. These cases provide a platform for discussing the complexities involved in selecting initial treatment regimens, recognizing signs of disease progression, and making timely adjustments to treatment plans.

This lecture library aims to enhance clinicians' understanding of routine follow-up measures to prevent clinical deterioration and to familiarize them with emerging evidence that can inform management strategies. It also delves into specific protocols for managing pregnant patients with PAH, a particularly high-risk group, ensuring that healthcare providers are equipped to navigate these challenging scenarios with confidence. By addressing these diverse learning objectives, this slide kit seeks to improve outcomes in patients facing the most severe manifestations of PAH.